| Code | CSB-RA3886MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar of Lu AG13909, designed to neutralize ACTH (adrenocorticotropic hormone) and thereby inhibit activation of MC2R (melanocortin 2 receptor; also known as the ACTH receptor), a GPCR primarily expressed in the adrenal cortex. Physiologically, ACTH–MC2R engagement triggers adenylate cyclase → cAMP/PKA signaling to drive adrenal steroidogenesis, supporting production of glucocorticoids (and, depending on adrenal zone context, mineralocorticoids and adrenal androgens).
Lu AG13909 is a humanized anti-ACTH IgG1 monoclonal antibody reported to block ACTH binding to MC2R in the adrenal glands and inhibit ACTH-induced melanocortin signaling; it has been investigated clinically in conditions characterized by chronically elevated ACTH (e.g., congenital adrenal hyperplasia and Cushing’s disease). This biosimilar provides the antibody component alone, enabling researchers to interrogate the ACTH–MC2R axis in controlled systems—such as ACTH-driven signaling readouts, adrenal steroid output (e.g., cortisol/androgen pathways), and pharmacology benchmarking versus receptor antagonism—without confounding variables from small-molecule MC2R inhibitors or other therapeutic modalities.
There are currently no reviews for this product.